Drugs / RBN-3143
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05215808 | Mar 2022 → Jun 2024 | atopic eczema | Ribon Therapeutics, Inc. | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RBN-3143 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05215808 ↗ |
| Action | Inhibit | “RBN-3143 is a PARP-14 inhibitor.” NCT05215808 ↗ |
| Route | Oral | “Oral Administration of tablets” NCT05215808 ↗ |